SureNano Science Advances GEP-44 Toward IND-Enabling Studies, Expands Investor Outreach

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has announced plans to advance its lead therapeutic candidate, GEP-44, into IND-enabling studies with LabCorp, a major step toward initiating Phase I clinical trials. The studies will focus on GLP toxicology and pharmacology, assessing safety, dosing parameters, and biomarkers across multiple species. GEP-44 is a next-generation GLP-1 agonist peptide designed to treat Type II diabetes and obesity, conditions affecting millions worldwide. The company aims to leverage improved tolerability and potential non-injectable delivery methods, which could differentiate it from existing therapies.

In parallel, SureNano is expanding its investor outreach through a strategic agreement with Investor Brand Network (IBN), which provides access to a syndication network of over 5,000 media outlets. This initiative is part of broader marketing engagements intended to strengthen market awareness and support the company's therapeutic pipeline. Additionally, SureNano is exploring early-stage discussions to acquire or license intellectual property related to ibogaine-based therapies, signaling a potential diversification into addiction and mental health treatments.

The IND-enabling studies represent a critical regulatory milestone, as they are required by the U.S. Food and Drug Administration before human trials can commence. Success in these studies would pave the way for Phase I trials, positioning SureNano to compete in the rapidly growing GLP-1 market, which is dominated by drugs like semaglutide. The company's focus on improved tolerability and non-injectable delivery could address key patient adherence issues.

SureNano's strategic shift from its original business of distributing the SureNano surfactant—a food-grade compound for nanoemulsions—to a pharmaceutical focus underscores its ambition to capture value in high-growth therapeutic areas. The acquisition of GlucaPharm Inc., which developed GEP-44, provides a patented peptide platform that the company believes has significant potential.

For more details, the full press release is available at https://ibn.fm/a6nGj. Additional updates on SureNano Science Ltd. can be found in the company's newsroom at https://ibn.fm/SURNF.